Álvaro Rodríguez-Lescure
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Álvaro Rodríguez-Lescure has a total of 266 co-authors. Here are the top co-authors by number of shared publications:
- Javier David Benitez Fuentes
Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain
8 shared publications - Emilio Alba
Hospital Clínico Universitario Virgen de la Victoria 9 Malaga
7 shared publications - Federico Rojo
Department of Pathology, Fundación Jiménez Díaz, Madrid, Spain
7 shared publications - Miguel Martín
Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
7 shared publications - Ana Santaballa
Department of Medical Oncology, La Fe University Hospital, IISLaFe, Valencia, Spain
6 shared publications - Cesar Augusto Rodriguez
Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
6 shared publications
Latest Publications
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (10)
Acute Oncology Services in Low- and Middle-Income Countries: Current Evidence, Challenges, and Strategic Priorities
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (10)
Acute Oncology Services in Low- and Middle-Income Countries: Current Evidence, Challenges, and Strategic Priorities
- Open Access
Access to cancer clinical trials in Europe: when trial availability does not match patient need
- 9 September 2026
- Published by Elsevier in Journal of Cancer Policy
- Vol. 50
Territorial inequality in oncology clinical trial participation and its ecological association with cancer mortality in Spain
- 9 September 2026
- Published by Elsevier in Journal of Cancer Policy
- Vol. 50
Territorial inequality in oncology clinical trial participation and its ecological association with cancer mortality in Spain
- Open Access
- 1 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3801-3811
Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial
Triple-negative breast cancer (TNBC) is an aggressive subtype with an activated tumor immune microenvironment. The multicenter, multinational, double-blinded NSABP B-59/GeparDouze trial evaluated the addition of atezolizumab (atezo) (773 patients randomized) or placebo (777 patients) to sequential taxane–carboplatin–anthracycline-based neoadjuvant chemotherapy in stage II–III TNBC. The addition of atezo did not significantly improve the primary endpoint of event-free survival (EFS) (HR, 0.80 (95% CI, 0.062–1.03); stratified log-rank P = 0.083, 4-year EFS rates difference 3.3%). The HR for overall survival was 0.86 (95% CI, 0.62–1.19), with a 4-year benefit of 0.7%. Prespecified subgroup analyses suggested heterogeneity in EFS, with benefit of atezo in patients presenting with clinical lymph node involvement ( P interaction = 0.039). Treatment-emergent adverse events with grades ≥3 were reported in 75.3% (atezo) versus 73.4% (placebo), and immune-related adverse events were reported in 27.6% (atezo) versus 11.4% (placebo). A total of 196 (25.5%) patients discontinued atezo and 143 (18.8%) patients discontinued placebo in the neoadjuvant phase. In an exploratory mRNA-based subset analysis, patients with basal-like immune-activated tumors may have benefited from atezo. TNBC subtyping to identify basal-like immune-activated tumors and quantification of tumor-infiltrating lymphocytes to identify tumors with high tumor-infiltrating lymphocyte counts could be a promising strategy to identify patients who benefit from the addition of immune checkpoint inhibitors to neoadjuvant chemotherapy. ClinicalTrials.gov registration: NCT03281954 .
- 1 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3801-3811
Open AccessAtezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial
Triple-negative breast cancer (TNBC) is an aggressive subtype with an activated tumor immune microenvironment. The multicenter, multinational, double-blinded NSABP B-59/GeparDouze trial evaluated the addition of atezolizumab (atezo) (773 patients randomized) or placebo (777 patients) to sequential taxane–carboplatin–anthracycline-based neoadjuvant chemotherapy in stage II–III TNBC. The addition of atezo did not significantly improve the primary endpoint of event-free survival (EFS) (HR, 0.80 (95% CI, 0.062–1.03); stratified log-rank P = 0.083, 4-year EFS rates difference 3.3%). The HR for overall survival was 0.86 (95% CI, 0.62–1.19), with a 4-year benefit of 0.7%. Prespecified subgroup analyses suggested heterogeneity in EFS, with benefit of atezo in patients presenting with clinical lymph node involvement ( P interaction = 0.039). Treatment-emergent adverse events with grades ≥3 were reported in 75.3% (atezo) versus 73.4% (placebo), and immune-related adverse events were reported in 27.6% (atezo) versus 11.4% (placebo). A total of 196 (25.5%) patients discontinued atezo and 143 (18.8%) patients discontinued placebo in the neoadjuvant phase. In an exploratory mRNA-based subset analysis, patients with basal-like immune-activated tumors may have benefited from atezo. TNBC subtyping to identify basal-like immune-activated tumors and quantification of tumor-infiltrating lymphocytes to identify tumors with high tumor-infiltrating lymphocyte counts could be a promising strategy to identify patients who benefit from the addition of immune checkpoint inhibitors to neoadjuvant chemotherapy. ClinicalTrials.gov registration: NCT03281954 .
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Forest plot for the GEICAM/9906 translational study cohort primary endpoint of DRFI, on the FEC vs FEC + P arms for SETER/PR cutpoint “0.75” categories.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Forest plot for the GEICAM/9906 translational study cohort primary endpoint of DRFI, on the FEC vs FEC + P arms for SETER/PR cutpoint “0.75” categories.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Representativeness of Study Participants.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Representativeness of Study Participants.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Patient and baseline characteristics of GEICAM/9906 hormone receptor positive (HR+) breast cancer cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Patient and baseline characteristics of GEICAM/9906 hormone receptor positive (HR+) breast cancer cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Bivariable Cox regression analysis of DRFI between SETER/PR index and EPclin risk score in the GEICAM/9906 translational study cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Bivariable Cox regression analysis of DRFI between SETER/PR index and EPclin risk score in the GEICAM/9906 translational study cohort.
- Open Access
- 2 July 2026
- Published by Elsevier in SSRN Electronic Journal
Territorial inequality in oncology clinical trial participation and cancer mortality in Spain: a longitudinal ecological study
Background: In Spain, universal coverage is delivered through 17 decentralised Autonomous Communities. We quantified territorial inequality in oncology clinical trial-participation density and examined its ecological association with age-standardised cancer mortality.Methods: We used a longitudinal ecological design with regions as the unit of analysis. Trial-participation density (participants per 100,000 population, 2016-2020) and annual authorised oncology trial counts (2015-2022) came from the Spanish Registry of Clinical Studies. Annual age-standardised cancer mortality came from the Spanish National Statistics Institute. Inequality was described with means, standard deviations, ranges, coefficients of variation, and maximum/minimum ratios. The main analysis used repeated-measures ecological models with calendar-year indicators and region-clustered standard errors, with sensitivity analyses for ageing, population weighting, GDP, post-exposure years, influence, HC3 errors, and wild cluster bootstrap inference.Results: Trial-participation density varied from 0.2 to 41.9 per 100,000 population (mean 15.0, SD 10.5; coefficient of variation 70.2%), a 209-fold regional difference. Mean cancer mortality excluding 2020-2021 varied less (mean 231.5, SD 11.7 per 100,000; coefficient of variation 5.1%). Mean mortality declined from 245.5 per 100,000 in 2015 to 216.5 in 2024. In the year-adjusted repeated-measures model, a 10-unit increase in trial-participation density was associated with -6.6 fewer cancer deaths per 100,000 (95% CI -12.0 to -1.3), equivalent to moving from the lowest to the median regional participation level. After ageing adjustment, the estimate was -5.5 (95% CI -10.3 to -0.7) per 10-unit increase. The post-exposure 2022-2024 analysis preserved the direction and similar magnitude of the association. Population weighting preserved the association, and GDP total attenuated it.Conclusions: In Spain, oncology trial participation is geographically concentrated. Regions with higher trial-participation density had persistently lower ecological cancer mortality, although the association is closely linked with metropolitan scale and oncology-system capacity. Trial infrastructure should be treated as a cancer-equity issue; causal interpretation requires finer geographic and patient-level data.
- 2 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTerritorial inequality in oncology clinical trial participation and cancer mortality in Spain: a longitudinal ecological study
Background: In Spain, universal coverage is delivered through 17 decentralised Autonomous Communities. We quantified territorial inequality in oncology clinical trial-participation density and examined its ecological association with age-standardised cancer mortality.Methods: We used a longitudinal ecological design with regions as the unit of analysis. Trial-participation density (participants per 100,000 population, 2016-2020) and annual authorised oncology trial counts (2015-2022) came from the Spanish Registry of Clinical Studies. Annual age-standardised cancer mortality came from the Spanish National Statistics Institute. Inequality was described with means, standard deviations, ranges, coefficients of variation, and maximum/minimum ratios. The main analysis used repeated-measures ecological models with calendar-year indicators and region-clustered standard errors, with sensitivity analyses for ageing, population weighting, GDP, post-exposure years, influence, HC3 errors, and wild cluster bootstrap inference.Results: Trial-participation density varied from 0.2 to 41.9 per 100,000 population (mean 15.0, SD 10.5; coefficient of variation 70.2%), a 209-fold regional difference. Mean cancer mortality excluding 2020-2021 varied less (mean 231.5, SD 11.7 per 100,000; coefficient of variation 5.1%). Mean mortality declined from 245.5 per 100,000 in 2015 to 216.5 in 2024. In the year-adjusted repeated-measures model, a 10-unit increase in trial-participation density was associated with -6.6 fewer cancer deaths per 100,000 (95% CI -12.0 to -1.3), equivalent to moving from the lowest to the median regional participation level. After ageing adjustment, the estimate was -5.5 (95% CI -10.3 to -0.7) per 10-unit increase. The post-exposure 2022-2024 analysis preserved the direction and similar magnitude of the association. Population weighting preserved the association, and GDP total attenuated it.Conclusions: In Spain, oncology trial participation is geographically concentrated. Regions with higher trial-participation density had persistently lower ecological cancer mortality, although the association is closely linked with metropolitan scale and oncology-system capacity. Trial infrastructure should be treated as a cancer-equity issue; causal interpretation requires finer geographic and patient-level data.
- Open Access
- 26 May 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (17) , 3870-3879
Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial
Purpose: To independently validate that low endocrine transcriptional activity measured by SETER/PR index in hormone receptor–positive breast cancer predicts benefit from dose-dense paclitaxel chemotherapy within a second prospective-retrospective biomarker study. Experimental Design: We conducted a blinded, prospective–retrospective biomarker analysis within the GEICAM/9906 trial (NCT00129922), which compared adjuvant FEC followed by weekly paclitaxel (FEC+P) versus six cycles of FEC in lymph node–positive breast cancer. SETER/PR index was measured in all available HR+/HER2– tumor RNA samples using a pre-specified cutpoint (<0.75). The primary endpoint was distant recurrence–free interval (DRFI); secondary endpoints were overall survival (OS) and breast cancer–specific survival (BCSS). Results: Of 647 HR+/HER2– tumors, 567 (87.6%) passed assay quality control (279 FEC+P; 288 FEC). Low SETER/PR index was identified in 92 tumors (16.2%). There was a significant interaction between SETER/PR status and treatment on DRFI (p=0.046). Among patients with low SETER/PR index, FEC+P significantly improved DRFI (HR 0.46; 95% CI, 0.22–0.95; p=0.035), with similar results after adjustment (HR 0.48; 95% CI, 0.24–1.00; p=0.049). No treatment benefit was observed for SETER/PR ≥0.75 (HR 1.02; 95% CI, 0.70–1.47; p=0.931). Differences in OS and BCSS did not reach significance. Conclusions: Low endocrine transcriptional activity predicts benefit from adding weekly paclitaxel to anthracycline-based adjuvant chemotherapy in HR+/HER2– breast cancer. These findings independently validate SETER/PR index as a predictive biomarker for paclitaxel-based chemotherapy and support its potential role in guiding regimen selection.
- 26 May 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (17) , 3870-3879
Open AccessSensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial
Purpose: To independently validate that low endocrine transcriptional activity measured by SETER/PR index in hormone receptor–positive breast cancer predicts benefit from dose-dense paclitaxel chemotherapy within a second prospective-retrospective biomarker study. Experimental Design: We conducted a blinded, prospective–retrospective biomarker analysis within the GEICAM/9906 trial (NCT00129922), which compared adjuvant FEC followed by weekly paclitaxel (FEC+P) versus six cycles of FEC in lymph node–positive breast cancer. SETER/PR index was measured in all available HR+/HER2– tumor RNA samples using a pre-specified cutpoint (<0.75). The primary endpoint was distant recurrence–free interval (DRFI); secondary endpoints were overall survival (OS) and breast cancer–specific survival (BCSS). Results: Of 647 HR+/HER2– tumors, 567 (87.6%) passed assay quality control (279 FEC+P; 288 FEC). Low SETER/PR index was identified in 92 tumors (16.2%). There was a significant interaction between SETER/PR status and treatment on DRFI (p=0.046). Among patients with low SETER/PR index, FEC+P significantly improved DRFI (HR 0.46; 95% CI, 0.22–0.95; p=0.035), with similar results after adjustment (HR 0.48; 95% CI, 0.24–1.00; p=0.049). No treatment benefit was observed for SETER/PR ≥0.75 (HR 1.02; 95% CI, 0.70–1.47; p=0.931). Differences in OS and BCSS did not reach significance. Conclusions: Low endocrine transcriptional activity predicts benefit from adding weekly paclitaxel to anthracycline-based adjuvant chemotherapy in HR+/HER2– breast cancer. These findings independently validate SETER/PR index as a predictive biomarker for paclitaxel-based chemotherapy and support its potential role in guiding regimen selection.